APEX Biologix entered into an exclusive distribution agreement with Bioventus for the XCELL PRP system throughout the U.S. for orthopedics and sports medicine applications.
The agreement allows APEX Biologix to leverage Bioventus’ national sales infrastructure in orthopedics and sports medicine to offer the XCELL PRP system to a broad range of orthopedic and sports medicine providers. XCELL PRP is designed to streamline procedures, optimize platelet concentration and support consistent clinical outcomes.
Bioventus will distribute the XCELL PRP system as part of its Pain Treatments portfolio.
“PRP is a large and fast-growing market, and our research indicates that most of our customers also use PRP in their practice,” said Anthony Doyle, General Manager, Pain and Restorative Therapies of Bioventus. “The APEX XCELL system offers a customizable treatment platform that enhances physician efficiency and reduces procedural time—key factors that provide a strong competitive advantage in this space.”
“We are assembling the best technology in autologous biologics, focused on specific applications and paired with top key opinion leaders in each market segment,” said Jim Rogers, CEO of APEX Biologix. “We’re excited to bring XCELL PRP to a broader physician base through Bioventus’ trusted channels and strong customer relationships.”
APEX Biologix entered into an exclusive distribution agreement with Bioventus for the XCELL PRP system throughout the U.S. for orthopedics and sports medicine applications.
The agreement allows APEX Biologix to leverage Bioventus’ national sales infrastructure in orthopedics and sports medicine to offer the XCELL PRP system to a broad range of...
APEX Biologix entered into an exclusive distribution agreement with Bioventus for the XCELL PRP system throughout the U.S. for orthopedics and sports medicine applications.
The agreement allows APEX Biologix to leverage Bioventus’ national sales infrastructure in orthopedics and sports medicine to offer the XCELL PRP system to a broad range of orthopedic and sports medicine providers. XCELL PRP is designed to streamline procedures, optimize platelet concentration and support consistent clinical outcomes.
Bioventus will distribute the XCELL PRP system as part of its Pain Treatments portfolio.
“PRP is a large and fast-growing market, and our research indicates that most of our customers also use PRP in their practice,” said Anthony Doyle, General Manager, Pain and Restorative Therapies of Bioventus. “The APEX XCELL system offers a customizable treatment platform that enhances physician efficiency and reduces procedural time—key factors that provide a strong competitive advantage in this space.”
“We are assembling the best technology in autologous biologics, focused on specific applications and paired with top key opinion leaders in each market segment,” said Jim Rogers, CEO of APEX Biologix. “We’re excited to bring XCELL PRP to a broader physician base through Bioventus’ trusted channels and strong customer relationships.”
Copy to clipboard 
